These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36702748)

  • 1. Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients.
    Pi MY; Cai CJ; Zuo LY; Zheng JT; Zhang ML; Lin XB; Chen X; Zhong GP; Xia YZ
    J Antimicrob Chemother; 2023 Mar; 78(3):792-801. PubMed ID: 36702748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with/without continuous renal replacement therapy.
    Luo X; Zhang Y; Liang P; Zhu H; Li M; Ding X; Zhang J
    Eur J Pharm Sci; 2022 Aug; 175():106214. PubMed ID: 35609779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation.
    Ye Q; Wang Q; Chen W; Zhang R; Chen Z; Li P; Zhang X; Zhan Q; Wang C
    J Clin Pharm Ther; 2022 Oct; 47(10):1608-1618. PubMed ID: 35716048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions.
    Yu XB; Jiao Z; Zhang CH; Dai Y; Zhou ZY; Han L; Wen X; Sheng CC; Lin GY; Pan JY
    Br J Clin Pharmacol; 2021 Apr; 87(4):1869-1877. PubMed ID: 33002196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of polymyxin B in different populations: a systematic review.
    Wang X; Xiong W; Zhong M; Liu Y; Xiong Y; Yi X; Wang X; Zhang H
    Eur J Clin Pharmacol; 2024 Jun; 80(6):813-826. PubMed ID: 38483544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration.
    Wang P; Xing H; Zhang F; Liu S; Lu Y; Zhang X; Yang J; Sun T
    Int J Antimicrob Agents; 2022 Jul; 60(1):106599. PubMed ID: 35526750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y; Cheng Z; Xie F
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
    Wang P; Liu D; Sun T; Zhang X; Yang J
    Int J Antimicrob Agents; 2022; 60(5-6):106693. PubMed ID: 36375775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Therapeutic Drug Monitoring of Polymyxin B During Continuous Renal Replacement Therapy in Two Pediatric Patients: Do Not Underestimate Extracorporeal Clearance.
    Xu C; Liu X; Cui Y; Huang X; Wang Y; Fan Y; Wu H; Li X; Guo B; Zhang J; Zhang Y
    Front Pharmacol; 2022; 13():822981. PubMed ID: 35401193
    [No Abstract]   [Full Text] [Related]  

  • 11. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative polymyxin B pharmacokinetics in patients receiving extracorporeal membrane oxygenation.
    Surovoy YA; Burkin MA; Galvidis IA; Bochkov PO; Oganesyan AV; Tsarenko SV
    J Antimicrob Chemother; 2022 Apr; 77(5):1379-1384. PubMed ID: 35134959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
    Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
    Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of the area under concentration-time curve of polymyxin B based on limited sampling concentrations in Chinese patients with severe pneumonia.
    Chen W; Liu H; Wang Q; Wang X; Kong X; Wang X; Zhang X; Zhan Q; Li P
    Eur J Clin Pharmacol; 2021 Jan; 77(1):95-105. PubMed ID: 32875388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
    He S; Cheng Z; Xie F
    Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections.
    Wang P; Zhang Q; Zhu Z; Feng M; Sun T; Yang J; Zhang X
    Front Pharmacol; 2020; 11():829. PubMed ID: 32581795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis.
    Surovoy YA; Burkin MA; Galvidis IA; Sobolev MA; Rende OC; Tsarenko SV
    Eur J Clin Pharmacol; 2023 Jan; 79(1):79-87. PubMed ID: 36378296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis.
    Wang P; Liu S; Sun T; Yang J
    Int J Antimicrob Agents; 2024 Mar; 63(3):107099. PubMed ID: 38280575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.